{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Boston&page=22&state=Massachusetts", "query": { "state": "Massachusetts", "city": "Boston", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 21483, "total_pages": 2149, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Boston&page=23&state=Massachusetts&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Boston&page=21&state=Massachusetts&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T18:00:01.007Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04551066", "title": "To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelofibrosis", "Primary Myelofibrosis", "Post Essential Thrombocythemia Myelofibrosis", "Post Polycythemia Vera Myelofibrosis" ], "interventions": [ { "name": "parsaclisib", "type": "DRUG" }, { "name": "ruxolitinib", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2021-05-24", "completion_date": "2024-11-25", "has_results": true, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-11-07T18:00:01.007Z", "location_count": 36, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Berkeley, California + 29 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04551066" }, { "nct_id": "NCT00620737", "title": "Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn Scars", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Restrictive Burn Scars of Joint Area" ], "interventions": [ { "name": "Autologous Human Fibroblasts (Isolagen TherapyTM)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Castle Creek Biosciences, LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2008-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-02-10", "last_synced_at": "2026-11-07T18:00:01.007Z", "location_count": 3, "location_summary": "Boston, Massachusetts • East Meadow, New York • Galveston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "East Meadow", "state": "New York" }, { "city": "Galveston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00620737" }, { "nct_id": "NCT05413239", "title": "Healthy And Positive Pathways for Young People With Type 1 Diabetes (HAPPY T1D)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Type 1 Diabetes" ], "interventions": [ { "name": "Psychoeducation to reduce diabetes distress and improve glycemic outcomes", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Joslin Diabetes Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "14 Years to 25 Years" }, "enrollment_count": 217, "start_date": "2022-07-26", "completion_date": "2026-02-01", "has_results": true, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-11-07T18:00:01.007Z", "location_count": 2, "location_summary": "Palo Alto, California • Boston, Massachusetts", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05413239" }, { "nct_id": "NCT02592330", "title": "Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Limbal Stem Cell Deficiency" ], "interventions": [ { "name": "Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft", "type": "PROCEDURE" }, { "name": "Cultivation of Limbal epithelial cells into a graft", "type": "BIOLOGICAL" }, { "name": "CALEC Transplant", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Massachusetts Eye and Ear Infirmary", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 23, "start_date": "2016-08-01", "completion_date": "2023-03-31", "has_results": true, "last_update_posted_date": "2025-01-15", "last_synced_at": "2026-11-07T18:00:01.007Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02592330" }, { "nct_id": "NCT03407170", "title": "Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Melanoma" ], "interventions": [ { "name": "pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2018-06-28", "completion_date": "2019-08-14", "has_results": true, "last_update_posted_date": "2020-07-15", "last_synced_at": "2026-11-07T18:00:01.007Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03407170" }, { "nct_id": "NCT00002305", "title": "A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Meningitis, Cryptococcal", "HIV Infections" ], "interventions": [ { "name": "Flucytosine", "type": "DRUG" }, { "name": "Fluconazole", "type": "DRUG" }, { "name": "Amphotericin B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-11-07T18:00:01.007Z", "location_count": 44, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002305" }, { "nct_id": "NCT01484002", "title": "Analysis of Crosslinked and Conventional Polyethylene Explants", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Osteoarthritis" ], "interventions": [ { "name": "Total hip arthroplasty", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Anderson Orthopaedic Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2011-12", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2017-01-24", "last_synced_at": "2026-11-07T18:00:01.007Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Alexandria, Virginia", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Alexandria", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01484002" }, { "nct_id": "NCT04493502", "title": "A Study of LY3041658 in Adults With Hidradenitis Suppurativa", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hidradenitis Suppurativa" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "LY3041658", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 72, "start_date": "2020-08-26", "completion_date": "2022-10-13", "has_results": true, "last_update_posted_date": "2023-04-28", "last_synced_at": "2026-11-07T18:00:01.007Z", "location_count": 15, "location_summary": "Rogers, Arkansas • Fountain Valley, California • Los Angeles, California + 12 more", "locations": [ { "city": "Rogers", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04493502" }, { "nct_id": "NCT02101853", "title": "Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent B Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Asparaginase", "type": "DRUG" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Mitoxantrone Hydrochloride", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Therapeutic Hydrocortisone", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "31 Years", "sex": "ALL", "summary": "1 Year to 31 Years" }, "enrollment_count": 669, "start_date": "2014-12-17", "completion_date": "2027-09-16", "has_results": true, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-11-07T18:00:01.007Z", "location_count": 166, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 135 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02101853" }, { "nct_id": "NCT04210037", "title": "Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "APG-1252", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascentage Pharma Group Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2020-08-20", "completion_date": "2022-05-15", "has_results": false, "last_update_posted_date": "2022-07-12", "last_synced_at": "2026-11-07T18:00:01.007Z", "location_count": 6, "location_summary": "Plantation, Florida • Atlanta, Georgia • Chicago, Illinois + 3 more", "locations": [ { "city": "Plantation", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04210037" } ] }